NRW.BANK
100% owned by Land Nordrhein-Westfalen
Also known as NRW.Venture, NRW Bank
Development bank of North Rhine-Westphalia, 100% owned by the Land; invests equity directly (NRW.Venture, up to €15m per start-up) and as LP in VC/PE funds; 62 companies and 72 funds at end-2024.
State development bank of North Rhine-Westphalia (Düsseldorf/Münster); not to be confused with KBG NRW (the NRW Mittelständische Beteiligungsgesellschaft) or with NBank (Lower Saxony).
- HEADQUARTERS
- Düsseldorf, Germany
- FOUNDED
- 2002
- AUM
- €1.3B (2024)
- OUTSIDE CAPITAL
- No — own capital only
- TEAM LISTED
- 19 people
Focus
- STAGES
- Pre-SeedSeedSeries ASeries BGrowthBuyout
- SECTORS
- Software & SaaSArtificial IntelligenceBiotech & Life SciencesHealthTechClimate & EnergyDeep TechIndustrial & Manufacturing
- ASSET MIX
- Direct investmentsVenture capitalFunds (as LP)
- GEOGRAPHY
- Germany
Investment arms & vehicles
- NRW.BANK's venture capital fund: minority stakes of up to €15m over several rounds in NRW start-ups, alongside private investors
- Fund launched February 2026 under InvestEU allowing total commitments of up to €30m in NRW scale-ups
- Seed co-investment programme
- Ruhr-region seed fund whose managing director and Prokurist come from the NRW.BANK venture team
Overview
NRW.BANK is the development bank of North Rhine-Westphalia, a public-law institution owned 100% by the Land NRW, with seats in Düsseldorf and Münster. Besides promotional loans it provides mezzanine and equity financing across the company life cycle, from pre-seed to growth, succession and restructuring, and invests in VC and PE funds. Through its venture capital fund NRW.Venture it takes minority stakes of up to €15m over several rounds in NRW start-ups alongside private investors; in February 2026 it launched NRW.Venture EU Tech&Scale, which allows up to €30m per scale-up as an InvestEU implementing partner. At 31 December 2024 its equity division held 62 companies and 72 funds.
Investment thesis
Minority equity stakes, over three to seven years, in innovative, often technology-oriented NRW start-ups that have closed a seed, business-angel or first VC round, co-investing with private investors; focus areas ICT/AI/enterprise software/IT security and life sciences/cleantech; fund investments to develop the VC and PE market in NRW.
PORTFOLIO (63)
- Biotech & Life Sciences
- Biotech & Life Sciences
- Deep Tech
- clockinSoftware & SaaS · since 2025
- HealthTech
- CylibClimate & Energy
- Biotech & Life Sciences
- eedenClimate & Energy · since 2025
- Deep Tech
- Biotech & Life Sciences · since 2026
- LidrotecIndustrial & Manufacturing · since 2025
- Biotech & Life Sciences
- Artificial Intelligence
- HealthTech
- Software & SaaS
- Software & SaaS
- Vytal GlobalClimate & Energy · since 2025
- Software & SaaS · Exited
- JUPUS GmbHArtificial Intelligence · since 2026
- eleQtron GmbHDeep Tech · since 2026
- Co-reactiveClimate & Energy · since 2026
- ag-tech.systems GmbHFood & Agriculture · since 2026
- SaperatecClimate & Energy
- InnolumeDeep Tech
- EnerthingClimate & Energy
- ubirchSoftware & SaaS
- Direvo Industrial BiotechnologyBiotech & Life Sciences
- Novihum TechnologiesClimate & Energy
- GreenPocketSoftware & SaaS
- Resolve BioSciencesBiotech & Life Sciences
- Deutsche Arzt AGHealthTech
- Personal MedSystemsHealthTech
- CellinkBiotech & Life Sciences
- octonomyArtificial Intelligence
- EnlyzeSoftware & SaaS
- HemoventHealthTech
- Femtos
- OcclutechHealthTech
- BomedusHealthTech
- CEVEC PharmaceuticalsBiotech & Life Sciences
- AyoxxA BiosystemsBiotech & Life Sciences
- Algiax PharmaceuticalsBiotech & Life Sciences
- aiforaSoftware & SaaS
- CompeonSoftware & SaaS
- RigontecBiotech & Life Sciences · Exited
- ScienionBiotech & Life Sciences · Exited
- evoxx technologiesBiotech & Life Sciences · Exited
- O-flexx TechnologiesClimate & Energy · Exited
- CellAct PharmaBiotech & Life Sciences · Exited
- Neo New OncologyBiotech & Life Sciences · Exited
- ProtagenBiotech & Life Sciences · Exited
- amberArtificial Intelligence · since 2026
- Talpasolutions GmbHSoftware & SaaS
- VTI Ventiltechnik GmbHIndustrial & Manufacturing
- Schoellershammer GmbHIndustrial & Manufacturing
- Phenox GmbHHealthTech · Exited
- Emergence Therapeutics AGBiotech & Life Sciences · Exited
- Frontastic GmbHSoftware & SaaS · Exited
- Holobuilder Inc.Software & SaaS · Exited
- Butlers GmbH & Co. KGConsumer & E-commerce · Exited
- d.velop AGSoftware & SaaS · Exited
People
- Gabriela PantringChair of the Managing Board (Vorsitzende des Vorstands) · source
- Dr. Peter StemperDeputy Chair of the Managing Board · source
- Claudia HillenhermsMember of the Managing Board · source
- Johanna Antonie Tjaden-SchulteMember of the Managing Board · source
- Dr. Claas HeiseHead of Venture Capital and fund investments (NRW.Venture) · source
- Dr. Thomas RaueiserHead of Life Sciences & Cleantech team; Prokurist, Gründerfonds Ruhr · source
- Thorsten ReuterHead of Digital Economy & Technology team; Managing Director, Gründerfonds Ruhr · source
- Thorsten HeldtSenior Investment Manager, Digital Economy & Technology (deputy team head) · source
- Dr. Marek KozlowskiSenior Investment Director, Life Science & Cleantech · source
- Massi Ali AhmadiInvestment Manager, Digital Economy & Technology · source
- Dr. Maria BräutigamInvestment Manager, Life Science & Cleantech · source
- Maximilian ErbInvestment team, Life Sciences & Cleantech · source
- Tim GudeljInvestment team, Digitalisation & Technology · source
- Philipp LeidigInvestment team, Life Sciences & Cleantech · source
- Dr. Vera Mehler-de GraaffInvestment team, Life Science & Cleantech · source
- Patrick NesselerInvestment Manager, Digital Economy & Technology · source
- Dr. Antonia NörthemannInvestment Manager, Digital Economy & Technology · source
- Florian StinauerInvestment team, Life Sciences & Cleantech · source
- Jonas VonnahmeInvestment team, Life Science & Cleantech · source
Links
Frequently asked questions
NRW.BANK is a government-backed fund based in Düsseldorf, Germany, founded in 2002.
Yes. NRW.BANK invests its own capital in private companies. It also commits capital to third-party funds as an LP.
NRW.BANK invests at Pre-Seed, Seed, Series A, Series B, Growth and Buyout stages in Software & SaaS, Artificial Intelligence, Biotech & Life Sciences, HealthTech, Climate & Energy, Deep Tech and Industrial & Manufacturing.
NRW.BANK's stated ticket size is €50K–€15M.
Key people at NRW.BANK include Gabriela Pantring (Chair of the Managing Board (Vorsitzende des Vorstands)), Dr. Peter Stemper (Deputy Chair of the Managing Board), Claudia Hillenherms (Member of the Managing Board) and Johanna Antonie Tjaden-Schulte (Member of the Managing Board).
NRW.BANK's investments include 4TEEN4 Pharmaceuticals, Abalos Therapeutics, Black Semiconductor, clockin, Cryotherapeutics, Cylib, Dimate and Disco Pharmaceuticals, among others.
The most recent publicly reported investment by NRW.BANK is ag-tech.systems GmbH (Seed), announced in Aug 2026.
NRW.BANK states that it accepts submissions through its official contact page.
No. NRW.BANK invests its own capital and does not raise money from outside investors.